Adjuvants are substances formulated as part of a vaccine to boost immune responses and enhance a vaccine's effectiveness.

Tuesday, June 29, 2021 Adjuvant Developed with NIAID Funding Enhances Efficacy of India's COVID-19 Vaccine This scanning electron microscope image shows SARS-CoV-2 (orange), the virus that causes COVID-19, emerging from the surface of cells (green) cultured in the lab. Credit: NIAID Rocky Mountain Labs An adjuvant developed with NIAID funding has contributed to the success of the highly efficacious COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere. Adjuvants are substances formulated as part of a vaccine to boost immune responses and enhance a vaccine's effectiveness. COVAXIN was developed and is manufactured in India, which is currently suffering a devastating health crisis due to COVID-19. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107